PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
13.68%
Cash & equivalents yoy growth 0.5-0.75x AGEN's 19.52%. Martin Whitman would worry if slower accumulation signals weaker operations or bigger outflows.
No Data
No Data available this quarter, please select a different quarter.
13.68%
Cash + STI yoy 0.5-0.75x AGEN's 19.52%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.59%
0.5-0.75x AGEN's 19.23%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-11.93%
Below half AGEN's 0.77%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-88.66%
Less than half of AGEN's 1.63%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-8.29%
≥ 1.5x AGEN's -1.47%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
13.10%
1.25-1.5x AGEN's 9.51%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
-14.12%
Less than half of AGEN's 14.47%. David Dodd sees a more disciplined AP approach or lower volume.
2.34%
Less than half of AGEN's 75.63%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
14.12%
Below half of AGEN's 32.82%. Michael Burry suspects a big gap in pre-sales traction.
-2.34%
Less than half of AGEN's -5.03%. David Dodd sees fewer expansions in other current obligations.
-12.65%
Less than half of AGEN's 6.54%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-36.66%
Above 1.5x AGEN's -0.55%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-14.12%
Less than half of AGEN's 1.61%. David Dodd sees far fewer liability expansions relative to competitor.
5.56%
Less than half of AGEN's 11.12%. David Dodd sees fewer share issuances vs. competitor.
-2.30%
0.5-0.75x AGEN's -3.66%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.36%
≥ 1.5x AGEN's 6.88%. David Dodd sees stronger capital base growth than competitor.
13.10%
1.25-1.5x AGEN's 9.51%. Bruce Berkowitz checks if expansions are well-justified by ROI.
No Data
No Data available this quarter, please select a different quarter.
-14.09%
Less than half of AGEN's 3.40%. David Dodd sees less overall debt expansion vs. competitor.
-14.00%
Less than half of AGEN's -39.87%. David Dodd sees better deleveraging or stronger cash buildup than competitor.